221 related articles for article (PubMed ID: 35740513)
1. Combined High-Throughput Approaches Reveal the Signals Driven by Skin and Blood Environments and Define the Tumor Heterogeneity in Sézary Syndrome.
Cristofoletti C; Bresin A; Fioretti M; Russo G; Narducci MG
Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740513
[TBL] [Abstract][Full Text] [Related]
2. Blood and skin-derived Sezary cells: differences in proliferation-index, activation of PI3K/AKT/mTORC1 pathway and its prognostic relevance.
Cristofoletti C; Bresin A; Picozza M; Picchio MC; Monzo F; Helmer Citterich M; Passarelli F; Frezzolini A; Scala E; Monopoli A; Cantonetti M; Benucci R; D'Atri S; Caprini E; Russo G; Narducci MG
Leukemia; 2019 May; 33(5):1231-1242. PubMed ID: 30518812
[TBL] [Abstract][Full Text] [Related]
3. Reduction of T Lymphoma Cells and Immunological Invigoration in a Patient Concurrently Affected by Melanoma and Sezary Syndrome Treated With Nivolumab.
Narducci MG; Tosi A; Frezzolini A; Scala E; Passarelli F; Bonmassar L; Monopoli A; Accetturi MP; Cantonetti M; Antonini Cappellini GC; De Galitiis F; Rosato A; Picozza M; Russo G; D'Atri S
Front Immunol; 2020; 11():579894. PubMed ID: 33072126
[TBL] [Abstract][Full Text] [Related]
4. Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling.
Mehdi SJ; Moerman-Herzog AM; Wong HK
J Vis Exp; 2021 Oct; (176):. PubMed ID: 34723945
[TBL] [Abstract][Full Text] [Related]
5. Genetically Driven CD39 Expression Affects Sezary Cell Viability and IL-2 Production and Detects Two Patient Subsets with Distinct Prognosis.
Picozza M; Cristofoletti C; Bresin A; Fioretti M; Sambucci M; Scala E; Monopoli A; Cantonetti M; Pilla MA; Accetturi MP; Borsellino G; D'Atri S; Caprini E; Russo G; Narducci MG
J Invest Dermatol; 2022 Nov; 142(11):3009-3019.e9. PubMed ID: 35533722
[TBL] [Abstract][Full Text] [Related]
6. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
7. Revisiting the initial diagnosis and blood staging of mycosis fungoides and Sézary syndrome with the KIR3DL2 marker.
Roelens M; de Masson A; Ram-Wolff C; Maki G; Cayuela JM; Marie-Cardine A; Bensussan A; Toubert A; Bagot M; Moins-Teisserenc H
Br J Dermatol; 2020 Jun; 182(6):1415-1422. PubMed ID: 31487384
[TBL] [Abstract][Full Text] [Related]
8. Improved Sézary cell detection and novel insights into immunophenotypic and molecular heterogeneity in Sézary syndrome.
Najidh S; Tensen CP; van der Sluijs-Gelling AJ; Teodosio C; Cats D; Mei H; Kuipers TB; Out-Luijting JJ; Zoutman WH; van Hall T; Orfao A; Almeida J; van Dongen JJM; Vermeer MH
Blood; 2021 Dec; 138(24):2539-2554. PubMed ID: 34314480
[TBL] [Abstract][Full Text] [Related]
9. A novel mouse model for Sézary syndrome using xenotransplantation of Sézary cells into immunodeficient RAG2(-/-) γc(-/-) mice.
van der Fits L; Rebel HG; Out-Luiting JJ; Pouw SM; Smit F; Vermeer KG; van Zijl L; Tensen CP; Weijer K; Vermeer MH
Exp Dermatol; 2012 Sep; 21(9):706-9. PubMed ID: 22897578
[TBL] [Abstract][Full Text] [Related]
10. The relevance of the CD4+ CD26- subset in the identification of circulating Sézary cells.
Bernengo MG; Novelli M; Quaglino P; Lisa F; De Matteis A; Savoia P; Cappello N; Fierro MT
Br J Dermatol; 2001 Jan; 144(1):125-35. PubMed ID: 11167693
[TBL] [Abstract][Full Text] [Related]
11. Histopathological and immunophenotypical criteria for the diagnosis of Sézary syndrome in differentiation from other erythrodermic skin diseases: a European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force Study of 97 cases.
Klemke CD; Booken N; Weiss C; Nicolay JP; Goerdt S; Felcht M; Géraud C; Kempf W; Assaf C; Ortonne N; Battistella M; Bagot M; Knobler R; Quaglino P; Arheiliger B; Santucci M; Jansen P; Vermeer MH; Willemze R
Br J Dermatol; 2015 Jul; 173(1):93-105. PubMed ID: 25864856
[TBL] [Abstract][Full Text] [Related]
12. Blockade of programmed cell death protein 1 (PD-1) in Sézary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferation.
Saulite I; Ignatova D; Chang YT; Fassnacht C; Dimitriou F; Varypataki E; Anzengruber F; Nägeli M; Cozzio A; Dummer R; Scarisbrick J; Pascolo S; Hoetzenecker W; Bobrowicz M; Guenova E
Oncoimmunology; 2020; 9(1):1738797. PubMed ID: 32760603
[TBL] [Abstract][Full Text] [Related]
13. Phenotypic plasticity of malignant T cells in blood and skin of a Sézary syndrome patient revealed by single cell transcriptomics.
Peiffer L; Gambichler T; Buus TB; Horny K; Gravemeyer J; Furtmann F; Spassova I; Kubat L; Susok L; Stranzenbach R; Srinivas N; Ødum N; Becker JC
Front Oncol; 2023; 13():1090592. PubMed ID: 36761972
[TBL] [Abstract][Full Text] [Related]
14. The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome.
Papadavid E; Economidou J; Psarra A; Kapsimali V; Mantzana V; Antoniou C; Limas K; Stratigos A; Stavrianeas N; Avgerinou G; Katsambas A
Br J Dermatol; 2003 Apr; 148(4):709-18. PubMed ID: 12752128
[TBL] [Abstract][Full Text] [Related]
15. Circulating clonal CLA(+) and CD4(+) T cells in Sezary syndrome express the skin-homing chemokine receptors CCR4 and CCR10 as well as the lymph node-homing chemokine receptor CCR7.
Sokolowska-Wojdylo M; Wenzel J; Gaffal E; Lenz J; Speuser P; Erdmann S; Abuzahra F; Bowman E; Roszkiewicz J; Bieber T; Tüting T
Br J Dermatol; 2005 Feb; 152(2):258-64. PubMed ID: 15727636
[TBL] [Abstract][Full Text] [Related]
16. Transcriptome sequencing in Sezary syndrome identifies Sezary cell and mycosis fungoides-associated lncRNAs and novel transcripts.
Lee CS; Ungewickell A; Bhaduri A; Qu K; Webster DE; Armstrong R; Weng WK; Aros CJ; Mah A; Chen RO; Lin M; Sundram U; Chang HY; Kretz M; Kim YH; Khavari PA
Blood; 2012 Oct; 120(16):3288-97. PubMed ID: 22936659
[TBL] [Abstract][Full Text] [Related]
17. CD158k and PD-1 expressions define heterogeneous subtypes of Sezary syndrome.
Vergnolle I; Douat-Beyries C; Boulinguez S; Rieu JB; Vial JP; Baracou R; Boudot S; Cazeneuve A; Chaugne S; Durand M; Estival S; Lablanche N; Nicolau-Travers ML; Tournier E; Lamant L; Vergez F
Blood Adv; 2022 Mar; 6(6):1813-1825. PubMed ID: 34570200
[TBL] [Abstract][Full Text] [Related]
18. Transcriptome analysis of Sézary syndrome and lymphocytic-variant hypereosinophilic syndrome T cells reveals common and divergent genes.
Moerman-Herzog AM; Acheampong DA; Brooks AG; Blair SM; Hsu PC; Wong HK
Oncotarget; 2019 Aug; 10(49):5052-5069. PubMed ID: 31489115
[TBL] [Abstract][Full Text] [Related]
19. The expression of cell adhesion molecule 1 and its splicing variants in Sézary cells and cell lines from cutaneous T-cell lymphoma.
Yamaguchi M; Morizane S; Hamada T; Miyake T; Sugaya M; Iwata H; Fujii K; Haramoto-Shiratsuki R; Nakagawa Y; Miura M; Ohshima K; Morishita K; Takahashi T; Imada M; Okada K; Uehara J; Sowa-Osako J; Iwatsuki K
J Dermatol; 2019 Nov; 46(11):967-977. PubMed ID: 31515833
[TBL] [Abstract][Full Text] [Related]
20. Sézary syndrome is a unique cutaneous T-cell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CDO1 and DNM3.
Booken N; Gratchev A; Utikal J; Weiss C; Yu X; Qadoumi M; Schmuth M; Sepp N; Nashan D; Rass K; Tüting T; Assaf C; Dippel E; Stadler R; Klemke CD; Goerdt S
Leukemia; 2008 Feb; 22(2):393-9. PubMed ID: 18033314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
